Latest Clinical Research News

Page 1 of 10
Archer Materials has moved its IonQ relationship into early commercial activity and advanced its Biochip towards external testing, but its graphene spin qubit demonstration is taking longer than expected. The company ended September with $A13.0 million in cash and an estimated 4.68 quarters of funding at its quarterly operating burn.
Victor Sage
Victor Sage
28 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
Anatara Lifesciences narrowed its FY2026 loss and ended the year with A$470,917 in cash, but warned that further capital raising is included in its business plan and may be necessary to remain a going concern. Its AOC anti-obesity candidate produced statistically significant results in mice, while mechanism-of-action data remained inconclusive and development was placed on hold.
Victor Sage
Victor Sage
23 Oct 2026
Cleo Diagnostics’ prototype ovarian cancer screening test met or exceeded every predefined performance target in a 247-person proof-of-concept study, including among 62 Stage I cases. The result moves the program into larger bridging and expanded studies, but it remains retrospective evidence rather than a validated screening test.
Ada Torres
Ada Torres
21 Oct 2026
Invion has secured two financing arrangements that could cover up to approximately 85% of its clinical trial costs, providing support for its skin cancer and planned anogenital cancer programs. The funding comes with potential dilution, 16% interest and conditions that leave the actual amount available dependent on drawdowns and R&D tax refunds.
Victor Sage
Victor Sage
21 Oct 2026
Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.
Ada Torres
Ada Torres
13 Oct 2026
Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.
Ada Torres
Ada Torres
13 Oct 2026
Optiscan Imaging has lodged a 510(k) submission for its InForm digital pathology device, moving the product from development into formal US regulatory assessment. FDA clearance is not assured, but a successful determination could open the door to commercial distribution in the company’s target market.
Victor Sage
Victor Sage
1 Oct 2026
LTR Pharma has completed the final Phase II pharmacokinetic report for SPONTAN, confirming a median 10-minute time to peak concentration against 60 minutes for an oral vardenafil tablet. The result completes the FDA-aligned dataset ahead of planned US submission work, although efficacy in erectile dysfunction patients remains to be tested.
Victor Sage
Victor Sage
1 Oct 2026
4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.
Victor Sage
Victor Sage
24 Sept 2026
Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.
Ada Torres
Ada Torres
22 Sept 2026
Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.
Ada Torres
Ada Torres
28 Aug 2026

Browse the archive

Full archive